EP1012238A4 - Peptide und mit peptiden beladene, antigen präsentierende zellen für die aktivierung von cytotoxischen t-zellen - Google Patents
Peptide und mit peptiden beladene, antigen präsentierende zellen für die aktivierung von cytotoxischen t-zellenInfo
- Publication number
- EP1012238A4 EP1012238A4 EP98906086A EP98906086A EP1012238A4 EP 1012238 A4 EP1012238 A4 EP 1012238A4 EP 98906086 A EP98906086 A EP 98906086A EP 98906086 A EP98906086 A EP 98906086A EP 1012238 A4 EP1012238 A4 EP 1012238A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- ctl
- peptides
- peptide
- activation
- presenting cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 230000004913 activation Effects 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3669697P | 1997-01-31 | 1997-01-31 | |
US36696P | 1997-01-31 | ||
PCT/US1998/001959 WO1998033888A1 (en) | 1997-01-31 | 1998-01-30 | Peptides and peptide-loaded antigen presenting cells for the activation of ctl |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1012238A1 EP1012238A1 (de) | 2000-06-28 |
EP1012238A4 true EP1012238A4 (de) | 2003-03-05 |
Family
ID=21890106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98906086A Withdrawn EP1012238A4 (de) | 1997-01-31 | 1998-01-30 | Peptide und mit peptiden beladene, antigen präsentierende zellen für die aktivierung von cytotoxischen t-zellen |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1012238A4 (de) |
JP (1) | JP2001509677A (de) |
AU (1) | AU6140998A (de) |
CA (1) | CA2278189A1 (de) |
WO (1) | WO1998033888A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
WO2001000225A1 (en) * | 1999-06-29 | 2001-01-04 | Epimmune Inc. | Hla binding peptides and their uses |
IT1309584B1 (it) * | 1999-02-26 | 2002-01-24 | San Raffaele Centro Fond | Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso. |
ATE445643T1 (de) * | 1999-11-18 | 2009-10-15 | Pharmexa Inc | Heteroklitische analoga von klasse-i epitopen |
CA2392764A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
AU2273701A (en) * | 1999-12-13 | 2001-06-18 | Epimmune, Inc. | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
US6602510B1 (en) | 2000-04-05 | 2003-08-05 | Epimmune Inc. | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
AU2001275490A1 (en) * | 2000-06-16 | 2002-01-02 | University Of Virginia Patent Foundation | MHC peptides over-expressed on prostate cancer cells and methods of use |
WO2002014481A1 (fr) | 2000-08-16 | 2002-02-21 | Takara Bio Inc. | Procede de culture extensive de lymphocytes t cytotoxiques specifiques de l'antigene |
WO2002020616A1 (en) * | 2000-09-01 | 2002-03-14 | Epimmune Inc. | Hla-a2.1 binding peptides and their uses |
AU2002257647A1 (en) * | 2001-03-09 | 2002-09-24 | Callistogen Ag | Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination |
AU2002305138A1 (en) | 2001-04-09 | 2002-10-21 | Mayo Foundation For Medical Education And Research | Methods and materials for cancer treatment |
TWI311586B (en) | 2001-08-15 | 2009-07-01 | Takara Bio Inc | Method of extended culture for antigen-specific cytotoxic t lumphocytes |
CN100591760C (zh) | 2002-03-25 | 2010-02-24 | 宝生物工程株式会社 | 制备细胞毒性淋巴细胞的方法 |
WO2004094454A2 (en) | 2003-04-18 | 2004-11-04 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
JPWO2005007694A1 (ja) * | 2003-07-16 | 2007-09-20 | 株式会社グリーンペプタイド | HER2/neuペプチドおよびその治療上の用途 |
US8927273B2 (en) | 2003-08-22 | 2015-01-06 | Takara Bio Inc. | Process for producing cytotoxic lymphocytes |
EP1715343B1 (de) * | 2005-04-20 | 2009-12-09 | F. Hoffmann-La Roche Ag | Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika |
EP1916302A4 (de) | 2005-08-17 | 2009-10-21 | Takara Bio Inc | Verfahren zur herstellung von lymphozyten |
WO2010086294A2 (en) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
KR20140068810A (ko) * | 2011-05-26 | 2014-06-09 | 지니우스 바이오테크놀로지 인베스트먼트, 엘엘씨 | 조절된 면역우세 요법 |
US10351824B2 (en) | 2011-12-12 | 2019-07-16 | Cell Medica Limited | Process of expanding T cells |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
HRP20221303T1 (hr) | 2012-02-09 | 2022-12-23 | Baylor College Of Medicine | SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI |
WO2017049291A1 (en) | 2015-09-18 | 2017-03-23 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
CN105175527B (zh) * | 2015-10-09 | 2021-06-04 | 深圳市康尔诺生物技术有限公司 | 一种乳腺癌特异性的热休克蛋白复合物及其应用 |
US11834675B2 (en) | 2015-12-30 | 2023-12-05 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
US20210380644A1 (en) * | 2018-10-26 | 2021-12-09 | Saint Louis University | Peptides for inducing heterosubtypic influenza t cell responses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656788B1 (de) * | 1992-08-07 | 2006-10-18 | Pharmexa Inc. | Hla bindepeptide und ihre verwendungen |
-
1998
- 1998-01-30 WO PCT/US1998/001959 patent/WO1998033888A1/en not_active Application Discontinuation
- 1998-01-30 EP EP98906086A patent/EP1012238A4/de not_active Withdrawn
- 1998-01-30 JP JP53317398A patent/JP2001509677A/ja not_active Ceased
- 1998-01-30 CA CA002278189A patent/CA2278189A1/en not_active Abandoned
- 1998-01-30 AU AU61409/98A patent/AU6140998A/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
BAKKER A B H ET AL: "GENERATION OF ANTIMELANOMA CYTOTOXIC T LYMPHOCYTES FROM HEALTHY DONORS AFTER PRESENTATION OF MELANOMA-ASSOCIATED ANTIGEN-DERIVED EPITOPES BY DENDRITIC CELLS IN VITRO", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 22, 15 November 1995 (1995-11-15), pages 5330 - 5334, XP002032191, ISSN: 0008-5472 * |
BOON T ET AL: "TUMOR ANTIGENS RECOGNIZED BY T LYMPHOCYTES", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, VOL. 12, PAGE(S) 337-365, ISSN: 0732-0582, XP000882320 * |
CHEN W-F ET AL: "IL-10 A NOVEL CYTOTOXIC T CELL DIFFERENTIATION FACTOR", JOURNAL OF IMMUNOLOGY, vol. 147, no. 2, 1991, pages 528 - 534, XP002220425, ISSN: 0022-1767 * |
KAWASHIMA I ET AL: "IDENTIFICATION OF GP100-DERIVED, MELANOMA-SPECIFIC CYTOTOXIC PRIMARY IN VITRO IMMUNIZATION WITH PEPTIDE-PULSED DENDRITIC CELLS. T-LYMPHOCYTE EPITOPES RESTRICTED BY HLA-A3 SUPERTYPE MOLECULES BY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 78, no. 4, 1998, pages 518 - 524, XP000917221, ISSN: 0020-7136 * |
ROMANI N ET AL: "PROLIFERATING DENDRITIC CELL PROGENITORS IN HUMAN BLOOD", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 180, no. 1, 1 July 1994 (1994-07-01), pages 83 - 93, XP000610046, ISSN: 0022-1007 * |
See also references of WO9833888A1 * |
TSAI V ET AL: "IDENTIFICATION OF SUBDOMINANT CTL EPITOPES OF THE GP 100 MELANOMA-ASSOCIATED TUMOR ANTIGEN BY PRIMARY IN VITRO IMMUNIZATION WITH PEPTIDE-PULSED DENDRITIC CELLS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, no. 4, 1997, pages 1796 - 1802, XP000919288, ISSN: 0022-1767 * |
YANG GUCHEN ET AL: "In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.", JOURNAL OF IMMUNOLOGY, vol. 155, no. 8, 1995, pages 3897 - 3903, XP002220424, ISSN: 0022-1767 * |
Also Published As
Publication number | Publication date |
---|---|
AU6140998A (en) | 1998-08-25 |
JP2001509677A (ja) | 2001-07-24 |
EP1012238A1 (de) | 2000-06-28 |
WO1998033888A1 (en) | 1998-08-06 |
CA2278189A1 (en) | 1998-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1012238A4 (de) | Peptide und mit peptiden beladene, antigen präsentierende zellen für die aktivierung von cytotoxischen t-zellen | |
SG49113A1 (en) | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl | |
HK1096974A1 (en) | Antibody against human parathormone related peptides | |
IL128529A0 (en) | Anti-inflammatory peptides and uses thereof | |
GB9701293D0 (en) | Reflector device and display incorporating same | |
ZA969444B (en) | Peptides which enhance transport across tissues and methods of identifying and using the same | |
AU7158398A (en) | Use of lentiviral vectors for antigen presentation in dendritic cells | |
ZA95261B (en) | T cell antigen receptor V region proteins and methods of preparation thereof | |
EP1055684A4 (de) | Tumorantigene in form von peptidderivaten | |
IL145850A0 (en) | Adhesion modulatory peptides and methods for use | |
GB9705903D0 (en) | VP22 Proteins and uses thereof | |
AU2768597A (en) | Novel peptides suitable for use in antigen specific immunosuppressive therapy | |
AU1598500A (en) | Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2 | |
AU6649698A (en) | Peptide probes to coil proteins and methods for making the same | |
AU4236097A (en) | Mhc peptides and methods of use | |
AU2087799A (en) | Diagnostic and therapeutic methods based upon valpha24jalphaq t cells | |
AU2408397A (en) | Ob protein receptor genes and use of the same | |
AU7308200A (en) | Novel hev antigenic peptide and methods | |
AU8010698A (en) | Method and device for enabling non-destructive determination of the elasticity of materials | |
AUPN024994A0 (en) | Assay and peptides for use therein | |
GB9714276D0 (en) | Peptides and related compounds | |
GB2336844B (en) | Anti-hiv peptides and proteins | |
AU8679498A (en) | Immunologically privileged cells and uses thereof | |
GB9704162D0 (en) | Assay methods and means | |
AU5915998A (en) | Battery belt assembly and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990812 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EPIMMUNE INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 9/08 B Ipc: 7C 12N 5/08 B Ipc: 7C 12N 5/06 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030121 |
|
18D | Application deemed to be withdrawn |
Effective date: 20020801 |